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Mutations induced in somatic cells and germ cells are responsible for a variety of human 
diseases, and mutation per se has been considered an adverse health concern since the early 
part of the 20th Century. Although in vitro and in vivo somatic cell mutation data are most 
commonly used by regulatory agencies for hazard identification, i.e., determining whether or 
not a substance is a potential mutagen and carcinogen, quantitative mutagenicity dose-
response data are being used increasingly for risk assessments. Efforts are currently underway 
to both improve the measurement of mutations and to refine the computational methods used 
for evaluating mutation data. We recommend continuing the development of these approaches 
with the objective of establishing consensus regarding the value of including the quantitative 
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Mutagenicity data most often are used in a dichotomous ‘screen and bin’ approach to identify 
mutagens (i.e., hazard identification or hazard ID) (Gollapudi, 2017). This paradigm is predicated 
on two assumptions: that mutagens are rare, and that they increase mutation frequencies 
above the ever-present background throughout the exposure range (i.e., there are no true 
thresholds). It has been known for some time, however, that neither of these assumptions are 
necessarily true. In general, mutagens are not rare. For instance, Zeiger and Margolin (2000) 
estimated that ~20% of the >60,000 organic compounds in commercial use are mutagenic and 
Snyder and Green (2001) found that 28.7% of marketed pharmaceutics with genetic toxicology 
data are positive in at least one standard genotoxicity test.  In addition, it is now commonly 
accepted that mutagenicity dose-response data, even for direct-acting alkylating agents, can 
have distinct non-linear responses. Low doses can display little or no apparent mutagenicity 
increases relative to the background, while higher doses show appreciable response increases, 
displaying at least ‘practical’ thresholds for mutagenicity (e.g., Doak et al., 2007; reviewed in 
Jenkins et al., 2010). 
 
Nevertheless, rather than being used quantitatively to establish an exposure limit, in most 
jurisdictions classification as a mutagen is used to modify the assumptions used in quantitative 
risk assessments for health outcomes such as cancer or reproductive damage.  This 
Commentary advocates recognition that mutation is a bona fide toxicological endpoint, and 
recommends employing quantitative analyses of dose-response mutagenicity data, along with 
other available toxicity information, to determine Health-Based Guidance Values (HBGVs) 
and/or Margins of Exposure (MOEs) for regulatory decision-making (ECHA, 2012; Dourson et al., 
2013; WHO, 2014; ICH, 2016, 2017; Hardy et al., 2017). 
Mutations in germ cells have been known to cause adverse effects on human health since the 
early 20th Century.  In this Special Issue, Marchetti et al. review germ cell mutagenesis, where a 
single mutation can result in a phenotype that affects the resulting offspring, e.g., Lesch-Nyhan 
syndrome, sickle cell anemia.  With somatic cell mutagenesis, mutants may clonally expand to a 
degree that affects the phenotype of an organ or tissue, with the expanded mutant cell 
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populations potentially contributing to a variety of diseases. Somatic cancer driver mutations 
confer phenotypic properties promoting cellular expansion and the malignancy of the resulting 
cell population (see Harris et al., this issue). Also, somatic mutations that are induced early in 
development can expand through normal cell division to populate a large portion of a tissue.  
Termed somatic mosaicism, these mixtures of wild-type cells and mutant cell clones are being 
increasingly recognized as a cause of human diseases other than cancer, e.g., paroxysmal 
nocturnal hemoglobinuria and perhaps autism (see article by Godschalk et al., this issue).  
Around the time that the Environmental Mutagen Society was founded, the attention of the 
regulatory community was directed toward the relationship between somatic cell mutation and 
cancer, and the use of short-term in vitro testing to rapidly and efficiently identify mutagens 
and potential carcinogens (Zeiger, 2004; White and Johnson, 2016; see article by DeMarini in 
this issue). The resulting screen-and-bin hazard ID paradigm led to a lack of emphasis on germ 
cell mutation and somatic mosaicism as health concerns. This was partially due to the absence 
of practical in vivo assays for these endpoints, particularly assays able to detect treatment-
induced gene mutations in humans and in the model rodent systems most relevant to health 
risk assessment. Although transgenic rodent (TGR) assays measure both germ cell and somatic 
cell mutations, these tests only became available after short-term tests for the identification of 
environmental mutagens had become established. Moreover, the use of TGR dose-response 
data for risk assessment is limited to genetically manipulated rodent models because the 
endpoint (transgene mutation) cannot be evaluated in humans or non-transgenic animals. 
Prior to the development of TGR assays, germ cell mutagenicity testing could be done, but it 
required extraordinary numbers of animals (e.g., Russell et al., 1998). With respect to somatic 
cell mosaicism, it has been demonstrated definitively in humans and animals (e.g., Lupski, 2013; 
Erickson, 2014; Mortazavi et al. 2003; McConnell et al., 2017; Meier et al., 2017; Luderer et al., 
2019; Yizhak et al., 2019); however, detection and analysis of mosaicism is challenging 
(Campbell et al., 2015) and there are no standardized strategies to specifically assess this 
endpoint. Currently, germ cell mutation is considered for toxicological risk assessments (e.g., 
Health Canada, 1993; United Nations, 2017), and Adverse Outcome Pathways (AOPs) have been 
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developed that treat germ cell mutation as an Adverse Outcome (Yauk et al., 2015b; Marchetti 
et al., 2016; see Sasaki et al., this issue). Because the phenotypes associated with a germ cell 
mutation have the potential to be expressed in offspring carrying the mutation, germ cell 
mutations conferring a phenotype are likely to cause adverse health effects. Accordingly, 
mutation is already considered as a bona fide toxicological endpoint in germ cells, and can be 
evaluated both in both qualitative and quantitative terms (reviewed by Marchetti et al., this 
issue). 
In contrast, several, often poorly understood steps must occur in the clonal expansion of cells 
with a somatic cell mutation before an adverse health effect becomes evident. Furthermore, 
many mutations and mutant clones with the potential for causing disease exist at low levels in 
apparently healthy individuals (e.g., Tomasetti, 2019; Yizhak et al., 2019; Harris et al., this 
issue).  Nevertheless, since useful methods to assess in vivo mutation in relevant species, 
including humans, now exist, and potentially better methods are on the horizon, they should be 
increasingly employed for generating mutation data that can be interpreted in a quantitative 
manner for regulatory decision-making. Because somatic mutations have a marked potential 
for causing adverse health effects, they, like germ cell mutations, should be considered Adverse 
Outcomes, as defined for the development of AOPs, and bona fide toxicological endpoints. With 
advances in our knowledge about the relationships between mutation and disease, it is 
conceivable that, in the future, mutation data also can be used routinely as a quantitative 
biomarker for cancer and other diseases associated with somatic mosaicism (see below).  
While the hazard ID paradigm has clear benefits in terms of screening substances for genotoxic 
activity and in prioritizing research and follow-up testing, there are several compelling benefits 
to using mutation as a toxicological endpoint. Relying solely on hazard ID testing effectively 
eliminates exposure to mutagens (and by extension, carcinogens) in regulated consumer 
products. An unintended consequence of eliminating exposure to any dose of a mutagen, 
however, might be the loss of potentially valuable substances (e.g., drugs) that are unlikely to 
induce mutations in humans, due to, for instance, the route or level of exposure, effective DNA 
repair at low doses, and/or active detoxification at low doses (MacGregor et al., 2015). Besides 
  11 September 2019 
6 
 
the loss of valuable products, the screen-and-bin paradigm also has the potential for the 
unnecessary diversion of resources to address existing exposures that have no practical 
consequence. In fact, endogenous exposure to known mutagens already occurs in humans (e.g., 
Nakamura et al., 2014).  In contrast, if mutation per se is considered a toxicological endpoint, 
and compensatory mechanisms (e.g., DNA repair or detoxification) acknowledged as affecting 
dose-responses, quantitative analysis of mutagenicity dose-response data can be used as the 
basis for risk assessments. More specifically, Point of Departure (PoD) metrics such as No 
Observed Adverse Effect Level (NOAEL) or Benchmark Dose (BMD), suitably adjusted using 
uncertainty/safety/adjustment factors, can be used to define human exposure limits, and such 
limits can be compared to actual human exposure data. This concept is not foreign to 
regulatory science, and indeed the following examples demonstrate that such concepts have 
been employed previously. 
 
Mutation as a toxicological endpoint: examples where dose-response data have been used 
In several instances quantitative interpretation of mutagenicity dose-response data have been 
used for risk assessment and regulatory decision-making. For example, in 2007, a batch of the 
AIDS drug Viracept became contaminated with a genotoxic carcinogen, ethyl methanesulfonate 
(EMS; Müller and Singer, 2009). In the absence of rodent tumor data suitable for assessing the 
cancer risk to exposed patients, the drug manufacturer, in consultation with the European 
Medicines Agency, the Committee for Medicinal Products for Human Use, and other experts, 
conducted a comprehensive toxicological evaluation of EMS that included an extensive in vivo 
mutagenicity study. Dose-response gene mutagenicity data generated using the transgenic 
MutaMouse, and dose-response micronucleus data from the mouse bone marrow 
micronucleus test, showed non-linear patterns for EMS genotoxicity. Their data supported the 
existence of a ‘practical threshold’ below which the likelihood of a response above background 
was negligible. The analysis indicated that the oral NOAEL for EMS-induced transgene mutation, 
i.e., the highest dose that failed to elicit a response significantly greater than the control, was 
454-fold greater than the maximum daily human intake of the EMS contaminant (Müller et al., 
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2009).  The data were used in a risk assessment of EMS, which concluded that patients using 
the contaminated drug product were unlikely to be at increased risk of cancer. 
In a more recent example, the Committee for Risk Assessment (RAC) of the European Chemicals 
Agency (ECHA) used mutagenicity data in responding to a European Commission request to 
evaluate the Occupational Exposure Limit (OEL) for benzene (ECHA, 2018).  A combination of 
epidemiological and experimental data indicated that bone marrow and the hematological 
system are targets for benzene-induced toxicity, with acute myeloid leukemia being the major 
health concern from occupational exposure. The RAC concluded that the carcinogenicity of 
benzene was closely associated with its aneugenicity and clastogenicity and that, in their 
opinion, the OEL could be a dose with a negligible risk of aneugenicity and clastogenicity in the 
bone marrow.  
In these two cases, mutation was used not only as a toxicological endpoint, but as a 
quantitative biomarker of an adverse outcome that is mechanistically linked to a particular 
disease, i.e., cancer. As indicated previously, the exact mechanistic and quantitative 
relationship between mutant frequency and cancer outcome is affected by many factors (see 
Harris et al., this issue). The regulators, however, considered the multiple lines of evidence 
indicating that mutations produced by environmental substances are causative factors in 
cancer, including cancer in humans, to be sufficiently strong for conducting quantitative 
assessments of risk. In the Viracept-EMS case, using the available mutation data as a basis for a 
regulatory decision was considered preferable to waiting for the results of a cancer bioassay 
before deciding on how best to protect the health of the affected patients.  
Finally, we cite two examples where dose-response mutation data were considered, but not 
used for the final risk assessment. In a regulatory decision regarding formaldehyde, the 
Bundesinstitut für Risikobewertung (BfR) decided that mutation was not the most appropriate 
quantitative biomarker for cancer so other toxicities were used for the risk assessment (BfR, 
2006). Thus, the cancer risk assessment conducted by the BfR was based on dose-response data 
for cytotoxicity and compensatory cell proliferation. Here, mutation (inferred from DNA 
damage) was one of the toxicological endpoints used by the BfR for conducting the risk 
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assessment, but as is common regulatory practice, the more sensitive endpoints were chosen 
for calculating HBGVs for formaldehyde exposure.  Similarly, in their screening assessment of 
natural gas condensates (NGCs) and NGC components, the Government of Canada 
quantitatively considered in vivo clastogenicity dose-response data. These genotoxicity dose-
response data, however, were deemed to be inadequate relative to those for other toxicities, 
which were ultimately used as the basis for the risk assessment (Environment Canada and 
Health Canada, 2016). 
 
Recent developments, issues, and possible advancements 
Encouraged by the acceptance of the risk assessment conducted in response to the Viracept 
contamination incident, the Genetic Toxicology Technical Committee (GTTC) of the Health and 
Environmental Sciences Institute (HESI) established a program to develop computational 
methods for analyzing genetic toxicology dose-response data, with the objective of selecting 
PoD metrics (e.g., NOGEL, BMD) for use in quantitative risk assessments (Gollapudi et al., 2013; 
Johnson et al., 2014). Some of the authors of this Commentary have been part of this effort 
(see White and Johnson, 2016), and the Commentary by White and Johnson in this Special Issue 
updates the status of these continuing efforts. Additionally, a case study described in this 
Special Issue outlines how these quantitative methods can be used to establish HBGVs for 
benzene (Luijten et al.). 
In the context of these case studies, the term ‘mutation’ encompasses both large and small 
sequence changes including the relatively small DNA sequence alterations associated with 
many gene mutations, as well as larger changes such as structural and numerical chromosomal 
aberrations. All of these genetic changes are at least potentially heritable, and all have been 
associated with human disease phenotypes (e.g., Campbell et al., 2015; Stenson et al., 2017).  
In the absence of information that would narrow the analysis to a particular class of mutation, 
as was the case with the benzene occupational exposure example described above, it is 
important to note that a comprehensive analysis of mutation as a toxicological endpoint would 
include gene mutation, clastogenicity, and aneugenicity. 
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Measuring both gene mutation and chromosomal mutations using standard genotoxicity 
assays, however, may not yield a comprehensive assessment of mutagenic activity because 
these assays have inherent limitations and biases. With gene mutation assays, only a single or a 
small number of loci are typically examined, and depending on the locus, the mutations 
detected are generally only a small subset of all possible genetic alterations. For TGR assays, 
base substitutions and small insertions and deletions are measured most commonly in a very 
specific target gene that has a different functionality than those that lead to disease (Lambert 
et al., 2005; Boverhof et al., 2011; Nohmi et al., 2017). Gene mutation, however, can be caused 
by megabase deletions, mitotic recombination spanning a large portion of a chromosome, and 
even aneuploidy (e.g., Wang et al., 2009). Also, mutagens differ not only by the types of 
sequence changes they cause, but where they cause them (Thilly, 1990; Chuang and Li, 2004; 
Lynch, 2010; Kucab et al., 2019); there are many examples demonstrating that mutations in 
both transgenes  and endogenous genes differ with respect to both frequency and type (Moore 
et al., 1989; DeMarini et al., 1989; Monroe et al., 1998; Walker et al., 1999). Differences in 
locus-specific mutation frequencies appear to be related to sequence context and methylation 
status, target size, overall gene structure, and chromosome type (i.e., autosomal versus sex-
determining). 
For chromosome mutations, the peripheral blood micronucleus assay measures the frequency 
of an induced response that is not heritable, although the mechanism involved in micronucleus 
formation is believed also to result in heritable structural and numerical chromosomal 
alterations. Likewise, the structural chromosome aberration assay directly measures known 
heritable aberrations only if special techniques are used (e.g., chromosome banding or 
painting).  
The TGR assay, and assays that can be conducted in both humans and rodents like the PIG-
A/Pig-a gene mutation assay and the peripheral blood chromosome aberration and MN assays, 
measure the appropriate endpoints in the appropriate species for assessing potential adverse 
outcomes. These assays, however, have limitations in terms of what they measure and the 
tissues and animal models that can be evaluated, and, thus, have the potential to give 
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imprecise measurements of mutation frequency. The justification for the quantitative 
interpretation of dose-responses from these assays can be summarized as follows. What is 
measured, both in humans and in animal models, is sufficiently related to the mutations 
actually caused by the exposure that they provide useful, if imprecise data for assessing and 
managing potential adverse health outcomes.  
We anticipate, however, that the newer error-corrected next generation sequencing (EC-NGS) 
technologies that directly measure mutations at any location in the genome or over the entire 
genome (Dong et al., 2017; Revollo et al., 2018; Guo et al. 2018; Zhang et al., 2019; see Salk, 
this issue) will: 1) provide a more comprehensive evaluation of smaller gene mutations and 
hence more appropriate estimates of mutation frequency; and, 2) be able to evaluate gene 
mutation in any tissue of any animal without the need for using transgene reporters.  With the 
use of longer-read NGS technologies, EC-NGS also may be able to evaluate chromosomal 
mutation. Although these novel methods have great promise for comprehensively quantifying 
mutations induced by exogenous agents, they require further development and validation 
before they can be used for regulatory applications.  
A final issue concerning the use of mutation as a toxicological endpoint is that quantitative 
evaluations of mutations, including the examples cited above, generally have used mutation in 
the context of cancer as the sole human health concern. While demonstrating the value of 
evaluating mutation quantitatively, this restricted focus may have limited how the analysis was 
performed. The International Workshops on Genotoxicity Testing (IWGT) committee report of 
Yauk et al. (2015) indicates that there are quantitative differences between the induction of 
germ cell and somatic cell mutations, and in some cases higher frequencies are detected for 
germ cell than somatic cell mutation. For example, 1,1,-dimethylhydrazine, dimethylni-
trosamine, diethylnitrosamine, and beta-propiolactone produced negative results for bone mar-
row micronucleus induction, an endpoint commonly used for cancer hazard assessment, but 
increased micronucleus frequencies in male rodent germline cells (Cliet et al., 1993; Yauk et al., 
2015).  Although some of these differences are undoubtedly due to differences in metabolism 
and the exposure of the tissues used for the assays, these observations suggest that it may not 
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be health-protective to assume that regulating on somatic cell effects, specifically those 
involved with cancer, also protects against germ cell mutation (for further discussion on this 
topic, see Marchetti et al., this issue). In addition, it may be sufficiently health-protective to 
measure somatic mutant frequencies without confirming clonal expansion, but it also may be 
necessary to evaluate transplacental mutagenesis to accurately quantify induced mutations 
involved in somatic mosaicism.  The value of evaluating mutation following transplacental 
exposure was recently demonstrated by Meier et al. (2017) who found that tissues like brain, 
which are resistant to mutation induction in adult animals, may be readily mutagenized by in 
utero exposure to a potent mutagen. 
All these issues make it a major challenge to evaluate the different types of mutations that 
occur in different tissues, at different life stages, and with differing manifestation times in a 
manner that is consistent with global initiatives to conserve animal resources. The current 
deliberations to revise the OECD Test Guideline for the TGR gene mutation assay (TG 488; 
OECD, 2013) indicate that it may be possible to devise a compromise protocol that is capable of 
measuring the induction of both somatic cell and germ cell mutation in a single set of animals 
with acceptable sensitivity (Marchetti et al., 2018a,b). Ideally, if mutation is to be used as a 
bona fide toxicological endpoint, its analysis should be integrated into standard repeat-dose 
toxicology studies (e.g., OECD TG 407, 415, and 422). It also may be possible to integrate 
mutagenicity assays into reproductive toxicity studies so that the induction of somatic 
mosaicism due to exposure during early developmental stages can be assessed. Integration into 
general toxicity or reproductive toxicity testing also may enable comparison of mutation data 
with other toxicity endpoints to establish the most sensitive endpoint to use in establishing a 
safe level of exposure, a common regulatory practice. There is currently resistance to using 
transgenic animals in general toxicology assays primarily due to lack of adequate comparative 
data with non-mutation endpoints in wild-type rodent strains. But, as noted above, EC-NGS 
may overcome this problem by allowing mutation analysis in any animal.   
 
Next steps 
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If increases in mutation induced by exogenous substances is a bona fide adverse health effect, 
as extensive scientific data indicate, we contend that regulatory risk assessments should treat 
mutation as a toxicological endpoint and employ quantitative analyses to determine exposure 
levels below which the risk of adverse outcomes (in this case mutation) can be deemed 
negligible (i.e., establish HBGVs). However, because our knowledge of how to use mutation 
data to quantitively assess disease outcomes requires further refinement, we are not currently 
recommending the next logical step, that quantitative mutation analysis routinely replace the 
measurement of tumors and other adverse health effects in making regulatory decisions. We 
do, however, suggest that this should be a long-term goal for the field of genetic toxicology. For 
the time being, however,  regulators who may be considering the use of mutation as a 
toxicological endpoint will benefit from a critical review of case studies that compare HBGVs 
and/or MOEs derived from mutagenicity studies with those derived from carcinogenicity 
studies or studies of other disease-endpoints. In addition, the following is recommended: 
1. Where possible, samples should be collected from ongoing cancer bioassays and other 
repeat-dose toxicity studies to enable parallel and/or future mutational analyses, e.g., 
for micronucleus, Pig-a mutation, and error-corrected NGS analysis (as done in 
Mittelstaedt et al., 2019). This recommendation applies to routine toxicology testing 
that is not normally conducted in TGRs. 
2. Advanced DNA sequencing methods should be validated for somatic and germ cell 
analyses so that they can be used to comprehensively measure induced mutations 
directly. 
3. Protocols and guidelines for designing and conducting regulatory mutation studies 
should be developed that enhance the utility of dose-response data for quantitative 
analysis and determination of HBGVs and/or MOEs. For example, assay guidelines 
should include recommendations regarding tissue selection, sampling times, number of 
doses, study design and animal allocation, acceptable data quality and background 
frequencies, possible assay integration, and computational approaches for dose-
response assessment. Current recommendations in OECD TGs should be adjusted to 
derive maximum value from dose-response data. 
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4. The uncertainty factors, also referred to as extrapolation or adjustment or safety 
factors, that are employed to calculate HBGVs and/or MOEs, should be scrutinized with 
respect to their applicability to mutagenicity. This complex issue, and the issues 
surrounding the quantitative interpretation of genotoxicity PoD values more generally, 
are more thoroughly discussed by White and Johnson in this Special Issue. 
 
Conclusions 
Mutations take different forms that require different analytical methods to detect, and their 
induction can differ quantitatively among tissues and particularly for different life stages: all of 
which makes a comprehensive analysis of mutagenesis extremely challenging. However, we 
argue that practical methods for considering mutation as a toxicological endpoint exist today, 
and that such methods already have been used for regulatory decisions. The well-established 
TGR assay can measure gene mutation in any tissue of transgenic rats and mice, and the MN 
and chromosome aberration assays, as well as the HPRT/Hprt and emerging PIG-A/Pig-a gene 
mutation assays, can be used to measure chromosome and gene mutations in both rodent 
models and humans. Information focusing the analysis on mutations associated with a 
particular health concern in specific tissues has been helpful in conducting these studies. 
Additional methods to comprehensively measure mutation and generate mutagenicity dose-
response data in both somatic and germ cells are developing rapidly, potentially increasing the 
value of mutation as an endpoint for regulating new and existing substances. In the not-too-
distant future, EC-NGS may overcome limitations of the current assays in terms of 
transferability between species and tissues and the range of genetic changes detected. 
Implementing quantitative methods for risk assessment will make better use of mutation data, 
and will be of value in mitigating the negative health outcomes of environmental exposures. 
Nevertheless, in light of current regulatory mandates, hazard ID approaches for interpretation 
of mutagenicity data will continue to be important for screening commercial products under 
development and for conducting regulatory decision-making; hazard ID data also can be used 
for prioritizing testing and designing follow-up studies. Integrating mutation analysis with other 
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toxicological endpoints not only optimizes the utilization of resources (e.g., personnel and 
animals), but also benefits the mutation-based risk assessment by providing the contextual data 
(e.g., data on absorption, distribution, metabolism and excretion, and non-neoplastic effects) 
that are gathered routinely in general toxicology testing. By establishing HBGVs and/or MOEs 
for mutation induction, procedures that are both pragmatic and beneficial to public health can 
be implemented for effectively managing the risk of mutations, and after appropriate 
validation, the incidence of diseases associated with mutations. Importantly, the uncertainty 
factors employed to routinely calculate HGBVs will need to be carefully considered prior to 
routine application of mutagenicity dose-response analysis in regulatory risk assessments. 
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